Menu
Fechar
hrs4r
 I want to donate
Firma
ANNA QUIROGA-VARELA
Position
Investigador/a Consolidat - R3
Established Researchers - R3
Projectes
Publicacions

Projectes

Neurodegeneration and Neuroinflammation

Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS) - Enfermedades Inflamatorias

Codi oficial: RD21/0002/0063 - EM Start date:01/01/2022 Data fi: 31/12/2025 Investigador/a principal: LLUÍS RAMIÓ TORRENTÀ Organisme finançador: INSTITUTO DE SALUD CARLOS III
Neurodegeneration and Neuroinflammation

PROCOGBIO Predicción de la progresión del deterioro cognitivo en la esclerosis múltiple combinando biomarcadores circulantes en sangre

Codi oficial: PI23/00517 Start date:01/01/2024 Data fi: 31/12/2026 Investigador/a principal: LLUÍS RAMIÓ TORRENTÀ, ANNA QUIROGA VARELA Organisme finançador: INSTITUTO DE SALUD CARLOS III
Neurodegeneration and Neuroinflammation

Prediciendo la Progresión del Deterioro Cognitivo en la Esclerosis Múltiple a través de biomarcadores circulantes en sangre (COGNIPROG)

Codi oficial: COGNIPROG Start date:01/09/2023 Data fi: 31/12/2025 Investigador/a principal: LLUÍS RAMIÓ TORRENTÀ Organisme finançador: ASOCIACIÓN ESCLEROSIS MULTIPLE ESPAÑA (AEDEM)
Neurodegeneration and Neuroinflammation

Terapia Génica para la Ataxia de Friedreich

Codi oficial: CPP2023-010463 Start date:01/09/2024 Data fi: 31/08/2027 Investigador/a principal: BERTA ALEMANY PERNA Organisme finançador: MINISTERIO DE ECONOMIA E INNOVACION
Neurodegeneration and Neuroinflammation

Ayuda de personal Miguel Servet

Codi oficial: CP24/00018 Start date:01/01/2025 Data fi: 31/12/2029 Investigador/a principal: ANNA QUIROGA VARELA Organisme finançador: INSTITUTO DE SALUD CARLOS III
Neurodegeneration and Neuroinflammation

EM-Line!Kids: rehabilitació cognitiva des de casa per a pacients en edat pediàtrica.

Codi oficial: 2024 PROD 00183 Start date:02/12/2024 Data fi: 01/06/2026 Investigador/a principal: JORDI GICH FULLÀ Organisme finançador: AGÈNCIA DE GESTIÓ UNIVERSITARIS I RECERCA
Neurodegeneration and Neuroinflammation

Red de Enfermedades Inflamatorias (REI)

Codi oficial: RD24/0007/0005 Start date:01/01/2025 Data fi: 31/12/2027 Investigador/a principal: LLUÍS RAMIÓ TORRENTÀ Organisme finançador: INSTITUTO DE SALUD CARLOS III
Neurodegeneration and Neuroinflammation

Ayuda de proyecto Miguel Servet

Codi oficial: CP24/00018 Projecte Start date:01/01/2025 Data fi: 31/12/2028 Investigador/a principal: ANNA QUIROGA VARELA Organisme finançador: INSTITUTO DE SALUD CARLOS III

Publicacions

Villacieros-alvarez, J, Lunemann, JD, Sepulveda, M, Valls-Carbó, A, Dinoto, A, Fernández, V, Vilaseca, A, Castillo, M, Arrambide, G, Bollo, L, Espejo, C, Llufriu, S, Blanco, Y, Armangue, T, Bravo, GA, Quiroga-Varela, A, Torrenta, LR, Cobo-Calvo, A, Tintore, M, Mariotto, S, Montalban, X, Comabella, M

Complement Activation Profiles Predict Clinical Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2025, 12 dx.doi.org/10.1212/NXI.0000000000200340
Fissolo N, Schaedelin S, Villar LM, Lünemann JD, Correale J, Rejdak K, Schwab N, Vilaseca A, Held F, García-Merino A, Bittner S, Trojano M, Furlan R, Tumani H, Pérez-Miralles F, Rosenstein I, Galimberti D, Álvarez-Bravo G, Thouvenot E, Llufriu S, Khoury SJ, Hoepner R, Martínez-Yélamos S, Hegen H, Drulovic J, Téllez-Lara N, Khalil M, Oechtering J, Pérez-Sempere Á, Rodríguez-Antigüedad A, Enrique-Martínez J, Strijbis E, Killestein J, Eichau S, Colombo E, Schaller-Nagengast J, Midaglia L, Sánchez-López AJ, Monreal E, Chan A, Paul F, Rovira À, Tintoré M, Lycke J, Zipp F, Hemmer B, Kuhle J, Montalban X, Comabella M, Zettl UK, Falk S, Gutiérrez L, Gasior M, Veiga González JL, Ferrer R, Quiroga-Varela A, Bachhuber F, Costa-Frossard L

Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome.

JAMA NEUROLOGY, 2025 dx.doi.org/10.1001/jamaneurol.2025.1481
Merino-Galán L, Zamarbide M, Belloso-Iguerategui A, Alonso-Moreno MC, Gago B, Reinares-Sebastián A, Blesa J, Dumitriu D, Quiroga-Varela A, Rodríguez-Oroz MC

Resilience of striatal synaptic plasticity over early structural adaptations in premotor parkinsonism.

npj Parkinsons Disease, 2025, 11, 146-146 dx.doi.org/10.1038/s41531-025-00994-1
Alemany-Perna, B, Tamarit, J, Cabiscol, E, Delaspre, F, Miguela, A, Huertas-Pons, JM, Quiroga-Varela, A, Ruiz, MM, Dominguez, DL, Torrenta, L, Genis, D, Ros, J

Calcitriol Treatment Is Safe and Increases Frataxin Levels in Friedreich Ataxia Patients

MOVEMENT DISORDERS, 2024, 39, 1099-1108 dx.doi.org/10.1002/mds.29808
Tortosa-Carreres J, Cubas-Núñez L, Quiroga-Varela A, Castillo-Villalba J, Ramió-Torrenta L, Piqueras M, Gasqué-Rubio R, Quintanilla-Bordas C, Sanz MT, Lucas C, Huertas-Pons JM, Miguela A, Casanova B, Laiz-Marro B, Pérez-Miralles FC

Predictive potential of serum and cerebrospinal fluid biomarkers for disease activity in treated multiple sclerosis patients.

MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 88, 105734-105734 dx.doi.org/10.1016/j.msard.2024.105734
Dominguez-Mozo MI, Galán V, Ramió-Torrentà L, Quiroga A, Quintana E, Villar LM, Costa-Frossard L, Fernández-Velasco JI, Villarrubia N, Garcia-Martinez MA, Arroyo R, Alvarez-Lafuente R

A two-years real-word study with fingolimod: early predictors of efficacy and an association between EBNA-1 IgG titers and multiple sclerosis progression.

Frontiers in Immunology, 2024, 15, 1384411-1384411 dx.doi.org/10.3389/fimmu.2024.1384411
Tortosa-Carreres, J, Cubas-Núñez, L, Piqueras, M, Castillo-Villalba, J, Quintanilla-Bordàs, C, Quiroga-Varela, A, Villarrubia, N, Monreal, E, Alvarez, G, Gasque-Rubio, R, Forés-Toribio, L, Carratala-Boscà, S, Lucas, C, Sanz, MT, Ramió-Torrentà, L, Villar, LM, Casanova, B, Laiz, B, Pérez-Miralles, FC

Evaluating the complement C1q levels in serum and cerebrospinal fluid in multiple sclerosis patients: Could it serve as a valuable marker in clinical practice?

JOURNAL OF NEUROIMMUNOLOGY, 2024, 394, 578428-578428 dx.doi.org/10.1016/j.jneuroim.2024.578428
Monreal E, Fernández-Velasco JI, Álvarez-Lafuente R, Sainz de la Maza S, García-Sánchez MI, Llufriu S, Casanova B, Comabella M, Martínez-Yélamos S, Galimberti D, Ramió-Torrentà L, Martínez-Ginés ML, Aladro Y, Ayuso L, Martínez-Rodríguez JE, Brieva L, Villarrubia N, Eichau S, Zamora J, Rodero-Romero A, Espiño M, Blanco Y, Saiz A, Montalbán X, Tintoré M, Domínguez-Mozo MI, Cuello JP, Romero-Pinel L, Ghezzi L, Pilo de la Fuente B, Pérez-Miralles F, Quiroga-Varela A, Rubio L, Rodríguez-Jorge F, Chico-García JL, Sainz-Amo R, Masjuan J, Costa-Frossard L, Villar LM

Serum biomarkers at disease onset for personalized therapy in multiple sclerosis.

Brain, 2024, 147, 4084-4093 dx.doi.org/10.1093/brain/awae260
Bravo, GCA, Quiroga-Varela, A, Gifreu, A, Pons, JMH, Lago, AB, Benavides, AM, Ramió-Torrentà, L

Echopraxia, an underrecognized clinical sign in multiple sclerosis: a biological and neuroimaging framework

MULTIPLE SCLEROSIS JOURNAL, 2024, 30, 743-743
Bravo, GCA, Gifreu, A, Quiroga-Varela, A, Lago, AB, Pons, JMH, Benavides, AM, Torrenta, LRI

First case of rebound effect after Ozanimod discontinuation

MULTIPLE SCLEROSIS JOURNAL, 2024, 30, 1081-1082

Formulari de contacte

About IDIBGI!

 menu